Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris

Inclusion Criteria:

-Has acne vulgaris on the face, including the nose, with 20 to 100 total lesions
(noninflammatory and/or inflammatory).

Exclusion Criteria:

- Has uncontrolled systemic disease(s)

- Has severe cystic acne, acne conglobata, acne fulminans, or secondary acne (chloracne,
drug-induced acne)

- Has used topical dapsone within 1 month prior to the screening

- Has used oral dapsone within 2 months prior to screening.